文献速递主动脉疾病

复杂EVAR术后贫血与输血对结局的影响

Impact of Postoperative Anemia and Transfusion in Patients Undergoing Complex Endovascular Aortic Aneurysm Repair.
PubMed 文献 · Ann Vasc Surg · 2025-06-17

基于VQI数据库2014—2020年4,966例接受复杂EVAR(含开窗分支及烟囱EVAR、累及1支及以上内脏肾动脉)的患者,按术后最低血红蛋白分层并比较输血状态。各血红蛋白组中接受输血者MACE均显著更高,多变量分析显示输血是MACE与院内死亡的独立预测因素;作者据此认为对无活动性出血的稳定患者以7 g/dL作为输血阈值有支持依据。

要点

  • 术后最低血红蛋白越低,输血比例越高,MACE、院内死亡与1年生存结局越差。
  • 在各血红蛋白分层中,接受输血者MACE均显著高于未输血者。
  • 除血红蛋白<7 g/dL组外,其余各组输血者院内死亡率显著更高。

核心结论

  • 复杂EVAR术后贫血与更差结局相关,输血并未减轻贫血的负面影响,而是与MACE和院内死亡增加独立相关。
  • 上述发现提示宽松输血可能存在潜在危害,并支持对无活动性出血的稳定患者以血红蛋白7 g/dL作为输血阈值。
  • 复杂EVAR患者的最佳输血阈值仍需进一步研究确定。

研究设计与样本

  • 回顾性查询血管外科学会血管质量倡议(VQI)数据库,纳入2014—2020年接受复杂EVAR(开窗分支或烟囱EVAR,且累及1支及以上内脏肾动脉)的患者,共4,966例符合分析标准。
  • 按术后最低血红蛋白水平分为<7、7-8、8-9、9-10、>10 g/dL五组,再按输血状态分层。
  • 主要终点为重大不良心脏事件(MACE,包括心肌梗死、心力衰竭、心律失常和卒中),次要终点为院内死亡和1年生存。

主要发现

  • 各血红蛋白分层占比:<7 g/dL为9%,7-8 g/dL为14%,8-9 g/dL为16%,9-10 g/dL为17%,>10 g/dL为43%。
  • 各血红蛋白分层输血率随最低血红蛋白升高而下降:<7、7-8、8-9、9-10、>10 g/dL组分别为89%、74%、40%、21%、6%。
  • MACE、院内死亡和1年生存与血红蛋白水平相关,血红蛋白最低组结局最差。
  • 各血红蛋白分层中输血者MACE均显著高于未输血者:<7 g/dL组33.42% vs 15.63%(P=0.048),7-8 g/dL组23.38% vs 14.04%(P=0.008),8-9 g/dL组18.69% vs 5.97%(P<0.0001),9-10 g/dL组14.44% vs 6.55%(P=0.0006),>10 g/dL组13.08% vs 3.43%(P<0.0001)。
  • 除血红蛋白<7 g/dL组外,其余各组输血者院内死亡率均显著高于未输血者;多变量分析显示输血仍是MACE和院内死亡的独立预测因素。

关键数值与推荐

  • 术后最低血红蛋白分层界值:<7、7-8、8-9、9-10、>10 g/dL。
  • 作者提出对无活动性出血的稳定患者以血红蛋白7 g/dL作为输血阈值。

临床怎么用

  • 复杂EVAR术后应关注最低血红蛋白水平,因其与MACE、院内死亡和1年生存相关。
  • 对无活动性出血的稳定患者,可考虑以血红蛋白7 g/dL作为输血阈值,宽松输血可能与MACE和院内死亡增加相关。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: While anemia in patients undergoing endovascular aortic repair (EVAR) has been associated with negative outcomes, the impact of transfusion remains unclear and controversial. This study evaluates the impact of postoperative anemia and red blood cell transfusion in patients undergoing complex EVAR (CEVAR) including fenestrated-branched and chimney EVAR. METHODS: The Society for Vascular Surgery Vascular Quality Initiative was queried for patients undergoing CEVAR with incorporation of 1 or more viscerorenal vessels from 2014 to 2020. Patients were grouped by postoperative nadir hemoglobin (Hgb) level (<7, 7-8, 8-9, 9-10, >10 g/dL), then stratified by transfusion status. The primary endpoint was major adverse cardiac events (MACE), including myocardial infarction, heart failure, dysrhythmia, and stroke. Secondary endpoints included in-hospital mortality and 1-year survival. RESULTS: In total, 4,966 patients met criteria for analysis including 9% with Hgb <7, 14% with Hgb 7-8, 16% with Hgb 8-9, 17% with Hgb 9-10, and 43% with Hgb >10. The rate of transfusion correlated inversely by lowest Hgb level: 89%, 74%, 40%, 21%, 6%, respectively. MACE, in-hospital mortality and 1-year survival correlated with Hgb level, with the worst outcomes in the lowest level. MACE was significantly higher for patients that received transfusion across all Hgb groups: 33.42% vs. 15.63%, P = 0.048; 23.38% vs. 14.04%, P = 0.008; 18.69% vs. 5.97%, P < 0.0001; 14.44% vs. 6.55%, P = 0.0006, and 13.08% vs. 3.43%, P < 0.0001, respectively. In-hospital mortality was significantly higher for patients that received transfusion in all groups except Hgb <7. On multivariable analysis transfusion remained an independent predictor for MACE and in-hospital mortality. CONCLUSION: Postoperative anemia in patients undergoing CEVAR is associated with worse outcomes. However, rather than attenuating the negative impact of anemia, transfusion is independently associated with increased MACE and in-hospital mortality. These findings suggest potential harm of liberal transfusion and support the practice of using a hemoglobin level of 7 g/dL as the threshold for transfusion in stable patients that are not actively bleeding. Further study is necessary to determine the optimal transfusion threshold for patients undergoing CEVAR.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. DiBartolomeo AD, Iyer AR, Plotkin A, et al. Impact of Postoperative Anemia and Transfusion in Patients Undergoing Complex Endovascular Aortic Aneurysm Repair. Ann Vasc Surg. 2025. PMID: 40553832. doi:10.1016/j.avsg.2025.06.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。